Involvement of ABC transporters in chemosensitivity of human renal cell carcinoma, and regulation of MRP2 expression by conjugated bilirubin

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2729-2736

  Nomura, Masaaki ^a   Matsunami, Toshio ^a   Kobayashi, Kayoko ^a   Uchibayashi, Tadao ^a,b   Koshida, Kiyoshi ^a,c   Tanaka, Motohiro ^b,d   Namiki, Mikio ^a   Mizuhara, Yasuharu ^d   Akiba, Tetsuo ^d   Yokogawa, Koichi ^a   Moritani, Shuzo ^e   Miyamoto, Ken Ichi ^a,d  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b Nanto Central Hospital   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e FUKUI PREFECTURAL UNIVERSITY   (Japan)

Author keywords

ABC transporter; Chemosensitivity; Conjugated bilirubin; MRP2; Renal cell carcinoma

Indexed keywords

ABC TRANSPORTER; BILIRUBIN GLUCURONIDE; CISPLATIN; COLLAGEN GEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 6;

ARTICLE; CANCER INHIBITION; CELL CULTURE; CHEMOSENSITIVITY; CONJUGATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME REGULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BILIRUBIN; CARCINOMA, RENAL CELL; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 22944451161     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Freeman AE and Hoffman RM: In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83: 2694-2698, 1986.
2. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH and Hoffman RM: In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 84: 5029-5033, 1987.
3. Ohyama S, Tanaka M, Yonemura Y, Kinoshita K, Miyazaki I and Sasaki T: In vitro chemosensitivity test of human gastric carcinomas using collagen gel matrix. Jpn J Cancer Res 82: 607-612, 1991.
4. Furukawa T, Kubota T and Hoffman RM: Clinical applications of the histoculture drug response assay: Clin Cancer Res 7: 305-311, 1995.
5. Ariyoshi Y, Shimahara M and Tanigawa N: Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol 39: 701-707, 2003.
6. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM and Shah J: Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24: 437-442, 2002.
7. Morioka H, Yabe H, Morii T, Yamada R, Kato S, Yuasa S and Yano T: In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res 21: 4147-4151, 2001.
8. Furukawa T, Kubota T, Tanino H, Oura S, Yuasa S, Murate H, Morita K, Kozakai K, Yano T and Hoffman RM: Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res 20: 3657-3658, 2000.
9. Hirano Y, Ushiyama T, Suzuki K and Fujita K: Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers: wide distribution of inhibition rates in bladder cancer and renal cell cancer. Urol Res 27: 483-488, 1999.
10. Uchibayashi T, Egawa M, Hisazumi H, Hasegawa T, Tanaka T and Sasaki T: In vitro chemosensitivity test for human genitourinary tumors using collagen gel matrix. Eur Urol 24: 267-270, 1993.
11. Minamino T, Nomura M, Tamai M, Moritani S, Ohshima T and Miyamoto K: In vivo cisplatin resistance of rat ascites hepatoma AH66. Cancer Lett 108: 153-156, 1996.
12. Minamino T, Tamai M, Itoh Y, Tatsumi Y, Nomura M, Yokogawa K, Suzuki H, Sugiyama Y, Ohshima T and Miyamoto K: In vivo cisplatin resistance depending upon canalicular multispecific organic anion transporter (cMOAT). Jpn J Cancer Res 90: 1171-1178, 1999.
13. Tamai M, Ito Y, Mirura H, Tsukada H, Yokogawa K, Nomura M, Moritani S and Miyamoto K: Conjugated bilirubin induces multidrug resistance-associated protein 2 mRNA expression and in vivo cisplatin resistance in rat hepatoma AH66 cells. Anticancer Res 23: 4781-4787, 2003.
14. Kruh GD and Belinsky MG: The MRP family of drug efflux pumps. Oncogene 22: 7537-7552, 2003.
15. Leonard GD, Fojo T and Bates SE: The role of ABC transporters in clinical practice. Oncologist 8: 411-424, 2003.
16. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH and Von Hoff DD: Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 70: 1379-1382, 1986.
17. Itoh Y, Tamai M, Yokogawa K, Nomura M, Moritani S, Suzuki H, Sugiyama Y and Miyamoto K: Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells. Anticancer Res 22: 1649-1653, 2002.
18. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
19. Cho YS and Kim MJ: Expression of multidrug resistance-related genes in oral squamous cell carcinomas. Oral Oncol 37: 652-659, 2001.
20. Soini Y, Jarvinen K, Kaarteenaho-Wiik R and Kinnula V: The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 12: 1239-1245, 2001.
21. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM and Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269, 1987.
22. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M and Kuwano M: A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 57: 5475-5479, 1997.
23. Cui Y, Konig J, Buchholz JK, Spring H, Leier I and Keppler D: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55: 929-937, 1999.